CBER Director Peter Marks and former FDA Deputy Commissioner Janet Woodcock (Greg Nash/Pool via AP Images; Michael Brochstein/Sipa USA/Sipa via AP Images)

FDA's Marks, Wood­cock talk reg­u­la­to­ry flex­i­bil­i­ty for new rare dis­ease drugs

The FDA’s top bi­o­log­ics chief and a for­mer deputy com­mis­sion­er on Tues­day dis­cussed the need for reg­u­la­to­ry flex­i­bil­i­ty for rare dis­ease ther­a­pies and un­der­scored the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.